Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
Cancer Research and Treatment · 15.10.2023 · 55 (4) · 1355-1362
DOI: 10.4143/crt.2023.271 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2023. Verfasst von Yu Ri Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Prednisolone, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PurposeThis phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL). Materials and MethodsNinety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy. ResultsAmong the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent grade 3 adverse events (40.0%) and 5 treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016). ConclusionRituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients. ClinicalTrials.gov ID: NCT01054781.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Hematology-Oncology Clinic, National Cancer Center, Goyang, Korea.
- Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
- Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Kim, Y. R., Kim, J. S., Kim, W. S., Eom, H. S., Yang, D. H., Bae, S. H., Kim, H. J., Lee, J. H., Oh, S. J., Yoon, S. S., Kwak, J. Y., Choi, C. W., Kim, M. K., Oh, S. Y., Kang, H. J., Nam, S. H., Shim, H., Park, J. S., Mun, Y. C., …, & Korean Society of Hematology Lymphoma Working Party (2023). Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study. Cancer Research and Treatment, 55(4), 1355-1362. https://doi.org/10.4143/crt.2023.271
Vancouver
Kim YR, Kim JS, Kim WS, Eom HS, Yang DH, Bae SH, et al. Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study. Cancer Research and Treatment. 2023;55(4):1355-1362. doi:10.4143/crt.2023.271
BibTeX
@article{Kim2023,
author = {Kim, Yu Ri and Kim, Jin Seok and Kim, Won Seog and Eom, Hyeon Seok and Yang, Deok-Hwan and Bae, Sung Hwa and Kim, Hyo Jung and Lee, Jae Hoon and Oh, Suk-Joong and Yoon, Sung-Soo and Kwak, Jae-Yong and Choi, Chul Won and Kim, Min Kyoung and Oh, Sung Young and Kang, Hye Jin and Nam, Seung Hyun and Shim, Hyeok and Park, Joon Seong and Mun, Yeung-Chul and Suh, Cheolwon and Korean Society of Hematology Lymphoma Working Party, Korean Society of Hematology Lymphoma Working Party},
title = {Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study},
journal = {Cancer Research and Treatment},
year = {2023},
volume = {55},
number = {4},
pages = {1355--1362},
doi = {10.4143/crt.2023.271}
}
EUVIMED